Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDK4/6i + Endocrine Therapy in Neoadjuvant Breast Cancer
NCT07366112Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer, sponsored by Peking University People's Hospital. Primary endpoint: ctDNA Clearance Rate. Started Apr 2026; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07366112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366112.